Free Newsletter
Zyprexa reps told to "neutralize" diabetes link
Free newsletter via e-mail
Tools
Documents unsealed in Alaska show that Eli Lilly sales reps touting Zyprexa were told to "neutralize the diabetes/hyperglycemia issue" that arose when doctors started pointing out that the drug might lead to the disease. "The competition wins when we are distracted into talking about diabetes," the documents state. Lilly says it hasn't downplayed Zyprexa's risks and that the documents are "a tiny fraction" of those provided as part of the Alaska lawsuit over the drug. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
